Aquaporumab  (Synonyms: AQmabAM; rAb-53)

Aquaporumab (AQmabAM) is an engineered human monoclonal IgG antibody. Aquaporumab is a selective inhibitor of aquaporin 4 (AQP4), binding tightly to AQP4 and competitively displacing AQP4-IgG from serum [1][2]. Aquaporumab significantly reduces neuromyelitis optica lesions in spinal cord slice cultures and in mice receiving intracerebral injection of AQP4-IgG and complement [1][2]. Aquaporumab can be used for research on neuromyelitis optica spectrum disorders [1][2]."}

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Aquaporumab competitively displaces AQP4-IgGs in NMO sera and prevents cytotoxicity, reducing NMO lesions in spinal cord slice cultures^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Aquaporumab reduces NMO lesions in mice receiving intracerebral AQP₄-IgG and complement^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

361  [NCBI]

P55087

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Duan T, et al. Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders. Neuropharmacology. 2020;162:107827.  [Content Brief]

  [2]. Verkman AS, et al. Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO. Brain Pathol. 2013;23(6):684-695.  [Content Brief]